Combination of PD1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer

Advanced pancreatic ductal adenocarcinoma (PDAC) is resistant to therapy, including immune checkpoint inhibitors. We evaluated the effects of a neutralizing antibody against programmed cell death 1 (PDCD1, also called PD1) and an agonist of OX40 (provides a survival signal to activated T cells) in mice with pancreatic tumors.

Source link

Related posts

Non-canonical Wnt signalling regulates scarring in biliary disease via the planar cell polarity receptors


FDA approves Dsuvia for acute pain management


Distinct phenotype of CD4+ T cells driving celiac disease identified in multiple autoimmune conditions


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy